Pancreatic Cancer Research

ResearcherUniversity of UtahActive in the last 2 years

Tatjana Crnogorac‐Jurcevic

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2465-5605; OpenAlex author ID A5027435550, A5146686504, A5158631206. Sources: ClinicalTrials.gov.

Their work

Papers
43 (first author 2, last author 21)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
101
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: 4 papers · 2018: 3 papers · 2019: 2 papers · 2020: 6 papers, 1 trial · 2021: 7 papers · 2022: 1 paper · 2023: 3 papers · 2024: 3 papers · 2025: 4 papers · 2026: 2 papers

Papers 43

  1. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  2. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  3. Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk. Co-author DOI 10.1002/ijc.35397↗
  4. A Clinical Laboratory Improvement Amendments/College of American Pathologists-Compliant Noninvasive Laboratory-Developed Test for Early Detection of Pancreatic… Co-author DOI 10.1016/j.jmoldx.2024.10.001↗
  5. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  6. Extracellular Vesicle-Derived miRNAs as Diagnostic Biomarkers for Pancreatic Ductal Adenocarcinoma: A Systematic Review of Methodological Rigour and Clinical A… Last author DOI 10.1177/11772719251381960↗
  7. Molecular characteristics of early-onset pancreatic ductal adenocarcinoma. Last author DOI 10.1002/1878-0261.13576↗
  8. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  9. Evaluation of urinary C-reactive protein as an early detection biomarker for pancreatic ductal adenocarcinoma. Last author DOI 10.3389/fonc.2024.1450326↗
  10. Urine biomarkers enable pancreatic cancer detection up to 2 years before diagnosis. Last author DOI 10.1002/ijc.34287↗
  11. S100PBP is regulated by mutated KRAS and plays a tumour suppressor role in pancreatic cancer. Last author DOI 10.1038/s41388-023-02851-y↗
  12. Nutraceuticals as Supportive Therapeutic Agents in Diabetes and Pancreatic Ductal Adenocarcinoma: A Systematic Review. First author DOI 10.3390/biology12020158↗
  13. Proteomes of Extracellular Vesicles From Pancreatic Cancer Cells and Cancer-Associated Fibroblasts. Co-author DOI 10.1097/mpa.0000000000002115↗
  14. Volatile organic compounds (VOCs) for the non-invasive detection of pancreatic cancer from urine. Co-author DOI 10.1016/j.talanta.2020.121604↗
  15. Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-021-00192-1↗
  16. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. Co-author DOI 10.1097/cej.0000000000000588↗
  17. A 3-Dimensional Coculture Model to Visualize and Monitor Interaction Between Pancreatic Cancer and Islet β Cells. Last author DOI 10.1097/mpa.0000000000001865↗
  18. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Co-author DOI 10.1136/gutjnl-2019-319990↗
  19. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Co-author DOI 10.1186/s13073-020-00816-4↗
  20. Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer-A Comprehensive Review. Last author DOI 10.3390/cancers13112722↗
  21. Discovery of novel small molecule inhibitors of S100P with in vitro anti-metastatic effects on pancreatic cancer cells. Co-author DOI 10.1016/j.ejmech.2020.112621↗
  22. Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients. Last author DOI 10.1038/s41416-019-0694-0↗
  23. Response to the comment on “Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients” First author DOI 10.1038/s41416-020-1014-4↗
  24. Urine metallomics signature as an indicator of pancreatic cancer. Last author DOI 10.1039/d0mt00061b↗
  25. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Co-author DOI 10.1158/1055-9965.epi-19-1027↗
  26. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. Last author DOI 10.1371/journal.pmed.1003489↗
  27. Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling. Last author DOI 10.1002/1878-0261.12463↗
  28. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. Co-author DOI 10.1002/ijc.31866↗
  29. Noninvasive Diagnosis of Pancreatic Cancer Through Detection of Volatile Organic Compounds in Urine. Last author DOI 10.1053/j.gastro.2017.09.054↗
  30. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Co-author DOI 10.1093/ije/dyx269↗
  31. Demographic, clinical, and pathological features of early onset pancreatic cancer patients. Last author DOI 10.1186/s12876-018-0866-z↗
  32. ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. Last author DOI 10.1038/onc.2016.459↗
  33. Splice variants as novel targets in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41598-017-03354-z↗
  34. A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. Co-author DOI 10.1093/annonc/mdx167↗
  35. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Co-author DOI 10.1136/gutjnl-2015-310442↗
  36. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-14-2467↗
  37. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. Last author PMID 26807325↗
  38. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13073-014-0105-3↗
  39. S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells. Last author DOI 10.1007/s10585-012-9532-y↗
  40. Molecular analysis of precursor lesions in familial pancreatic cancer. Co-author DOI 10.1371/journal.pone.0054830↗
  41. Proteome of formalin-fixed paraffin-embedded pancreatic ductal adenocarcinoma and lymph node metastases. Last author DOI 10.1002/path.3959↗
  42. S100P-binding protein, S100PBP, mediates adhesion through regulation of cathepsin Z in pancreatic cancer cells. Last author DOI 10.1016/j.ajpath.2011.12.031↗
  43. AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Last author DOI 10.1158/0008-5472.can-11-1367↗

Trials 1

  1. Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers Principal investigator NCT04449406↗

Closest collaborators

The 25 strongest of 101 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Silvana Debernardi · 8 shared papers, 2015–2025 · strength 1.24
  2. Oleg B. Blyuss · 7 shared papers, 2020–2025 · strength 1.21
  3. Núria Malats · 11 shared papers, 2015–2025 · strength 0.89
  4. William Greenhalf · 11 shared papers, 2015–2025 · strength 0.89
  5. Francisco X. Real · 10 shared papers, 2015–2025 · strength 0.80
  6. Rita Teresa Lawlor · 9 shared papers, 2017–2025 · strength 0.79
  7. Aldo Scarpa · 11 shared papers, 2014–2024 · strength 0.78
  8. Luis Muñoz‐Bellvís · 9 shared papers, 2017–2025 · strength 0.76
  9. J. Enrique Domínguez‐Muñoz · 9 shared papers, 2017–2025 · strength 0.76
  10. Alfredo Carrato · 9 shared papers, 2017–2025 · strength 0.76
  11. Jorg H. Kleeff · 9 shared papers, 2017–2025 · strength 0.76
  12. Thomas Mathias Gress · 9 shared papers, 2017–2025 · strength 0.76
  13. Hemant Mahendrakumar Kocher · 10 shared papers, 2012–2021 · strength 0.75
  14. Eithne Costello · 10 shared papers, 2015–2024 · strength 0.71
  15. Matthias J. Löhr · 8 shared papers, 2017–2025 · strength 0.62
  16. Linda Sharp · 8 shared papers, 2017–2024 · strength 0.58
  17. Bo Kong · 8 shared papers, 2017–2024 · strength 0.58
  18. Christoph W. Michalski · 7 shared papers, 2017–2024 · strength 0.54
  19. Jian Tajbakhsh · 2 shared papers, 2024–2025 · strength 0.46
  20. Stephen Jacob Pandol · 2 shared papers, 2024–2025 · strength 0.46
  21. Nirdesh K. Gupta · 2 shared papers, 2024–2025 · strength 0.46
  22. Kirtiman Srivastava · 2 shared papers, 2023 · strength 0.45
  23. Paulina Gómez-Rubio · 7 shared papers, 2017–2021 · strength 0.44
  24. RK Patel · 1 shared paper, 2025 · strength 0.42
  25. Weimin Ye · 5 shared papers, 2018–2024 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.